Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
UL16-binding protein 2 (ULBP2) is a membrane-bound or secreted MHC class I-related glycoprotein encoded on human chromosome 6, structurally lacking the α3 domain typical of classical MHC I molecules. It is a stress-induced ligand for the activating NKG2D receptor found on natural killer (NK) cells and some T cell subsets, promoting cytotoxic responses and the release of immune-modulating cytokines. ULBP2 plays a central role in immune surveillance against cancer and virus-infected cells; however, tumors frequently exploit ULBP2 by secreting or dysregulating its expression to escape immune detection. Overexpression of ULBP2 correlates with tumor progression and worse survival in multiple malignancies, making it a researched immunotherapeutic target and prognostic marker[1][2][3][5][6][7].
ULBP2 serves as a ligand for the NKG2D receptor on NK and some T cells, leading to immune cell activation, cytotoxicity, and cytokine release. Some tumor cells overexpress or shed ULBP2 to evade immune detection, reducing efficacy of immunosurveillance[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on UL16-binding protein 2 (ULBP2).